Latest News
AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer
1 September 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) on Tuesday announced European Commission approval for Enhertu (trastuzumab de...
NeuroSense reveals strategy to advance PrimeC toward potential ALS approval
1 September 2026 - NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing novel treatments for neurodegenerative diseases, announced on Monday a redesigned development plan for PrimeC in amyotrophic lateral ...
Prasco increases Ohio pharmaceutical footprint
1 September 2026 - Prasco LLC, a pharmaceutical commercialisation company specialising in authorised generics, today announced on Monday the acquisition of a strategically located distribution facility in Carey, Ohio.Prasco said that the 130,000+ squ...
UCB agrees with US government to lower medicine costs and strengthen US manufacturing
1 September 2026 - Belgium-based biopharmaceutical company UCB (EBR:UCB) announced on Monday that it has reached an an agreement with the US government that will continue to support patient access to important medicines while enabling significant inv...
BioArctic and Eisai announce final positive recommendation from Canada's Drug Agency supporting public reimbursement of Leqembi
1 September 2026 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its Japanese partner Eisai Co Ltd (TYO:4523) announced on Tuesday that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public r...